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Summary. Varying results on the effect of factor XIII (FXIII)
Val34Leu on venous thrombotic risk have been reported.
The probability of a true association between this poly-
morphism and venous thrombotic risk would be enhanced
by a laboratory phenotype associated with this poly-
morphism and with the thrombotic risk. The aim of this
study was to assess the effect of FXIII VaB4Leu, FXIII
activity and subunit levels on venous thrombotic risk in a
large case-control study, The Leiden Thrombophilia study
(LETS). We found higher FXIII activity for 34Leu carriers
(Leu/Leu: 158-0, Val/Val: 95Ό). FXIII subunit levels were
not associated with genotype. Higher FXIII activity was
associated with a slightly decreased thrombotic risk [Odds
ratio (OR): 0-8, 95% confldence intervals (CI): 0-5-1-3].
This effect was not present for elevated FXIII subunit levels.
Higher FXIII activity was also associated with a higher
dissociation index (percentage Α·^>2 complex dissociated
after activation by thrombin for a flxed time interval). This
index was higher for FXIII 34Leu carriers. The risk of deep
venous thrombosis was slightly decreased for carriers of the
34Leu allele [OR: 0-9 (95%CI: 0-7-1-1)]. For homozygous
34Leu carriers the OR was 0-7 (95%CI: 0-4-1-3). This
flnding, suggesting a weak protective effect, was completely
restricted to men. An overall estimate of thrombotic risk
was calculated by using earlier reports on the risk of FXIII
Val34Leu. The overall risk estimate for homozygous 34Leu
carriers was 0-8 (95%CI: 0-6-1-0). In this study, a weak
protective effect against venous thrombosis was found, of
FXIII 34Leu äs well äs of increased FXIII activity.
Keywords: factor XIII activity, factor XIII subunit levels,
Val34Leu polymorphism, venous thrombosis.
Earlier studies revealed varying results on the thrombotic
effect of a common polymorphism (G —> T) in exon 2 of the
gene coding for the A subunit of factor XIII (FXIII). Some
studies indicated that this polymorphism may be associated
with protection against venous thrombosis (Catto et al,
1999; Franco et al, 1999; Alhenc-Gelas et al, 2000; Renner
et al, 2000) while other studies reported no effect of this
polymorphism on the risk of deep venous thrombosis
(Balogh et al, 2000; Corral et al, 2000; Margaglione et al,
2000).
Several studies also suggested that the factor XIII 34Leu
allele protects against myocardial infarction (Kohler et al,
1998a; Wartiovaara ei al, 1999; Franco et al, 2000a) and
ischaemic stroke (Elbaz et al, 2000), whereas it has been
associated with an increased risk for haemorrhagic stroke
(Catto et al, 1998).
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The G to T polymorphism predicts the replacement of
Valine-34 by Leucine in the activation peptide, only three
amino acids from the thrombin cleavage site (Mikkola et al,
1994).
As described by Lane & Grant (2000), in order for a
genetic polymorphism to have an effect on disease, it has to
be mediated through a phenotype.
Factor XIII Val34Leu is one of several common poly-
morphisms in the coding region of the factor XIII gene
which are not associated with factor XIII deflciency
(Mikkola et al, 1994; Suzuki et al, 1996). Factor ΧΙΠ
34Leu has been associated with increased factor XIII
activity (Kangsadalampai & Board, 1998; Kohler et al,
1998b; Anwar et al, 1999) but not with higher levels of A
and B subunit antigen (Kohler et al, 1998b; Balogh et al,
2000). After füll activation, however, the speciflc cross-
linking activity does not differ (Ariens et al, 2000; Warti-
ovaara et al, 2000), suggesting that the polymorphism
affects activation rates rather than cross-linking activity
itself.
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Recent evidence indicates that the catalytic efficiency of
thrombin-induced cleavage of factor XIII 34Leu is two to
threefold higher than that of factor XIII 34Val (Ariens et al,
2000; Wartiovaara et al, 2000). The accelerated activation
of factor XIII 34Leu has beert shown to alter the structure of
the cross-linked fibrin. Early covalent cross-linking by factor
XIII 34Leu inhibits lateral aggregation of the fibrin obres,
whereas delayed cross-linking by factor XIII 34Val will
allow for more lateral aggregation (Ariens et al, 2000). A
fibrin clot cross-linked by factor XIII 34Leu is characterized
by reduced pore size and fibres with a reduced mass-length
ratio. These changes in clot structure may affect the risk of
thrombosis and haemorrhagic events.
At present, little is known about the effect of the
laboratory phenotype associated with this polymorphism
on the risk of venous thrombosis. In order to understand if
and how the factor XIII Val34Leu polymorphism affects the
risk of deep venous thrombosis, it is important to establish
the relationship between this polymorphism and factor XIII
protein levels or activity and their effect on thrombotic risk.
The aim of this study was therefore to assess the relation-
ship between factor ΧΙΠ Val34Leu, factor XIII A and B
subunit levels, factor XIII activity and D-dimer levels in a
large case-control study, and to assess the effect of this
genotype and the laboratory phenotypes on venous throm-
botic risk.
MATERIALS AND METHODS
Study design. This study was part of a large population-
based case-control study on risk factors for venous throm-
bosis, the Leiden Thrombophilia study (LETS). The design of
this study has been described in detail previously (Koster
et al, 1993; van der Meer et al, 1997). In brief, we included
474 consecutive patients younger than 70 years, with a
flrst objectively diagnosed episode of deep venous thrombo-
sis that occurred in the period between l January 1988 and
31 December 1992. Subjects were selected from the files of
the anticoagulation clinics in Leiden, Amsterdam and
Rotterdam. We also included 474 population control
subjects who were friends or partners of the patients. The
control subjects were of the same sex and approximately the
same age (± 5 years) äs the patients. Blood was collected
from the antecubital vein into Sarstedt Monovette® tubes, in
0-1 volume 0-106 mol/1 trisodium citrate. Plasma was
prepared by centrifugation for 10 min at 2000 g at room
temperature and stored at -70°C until used. High-molecu-
lar-weight DNA was isolated from leucocytes and stored at
4°C.
Factor XIII activity and subunit levels. The factor XIII
activity and factor XIII A and B subunil antigen were
measured äs described previously (Ariens et al, 1999). Factor
XIII activity was measured with a microtitre assay using
flbrinogen and S-(biotinamido) pentylamine äs Substrates,
adapted from a method previously described by Song et al
(1994). The assay is based on the measurement of the
amount of biotinylated pentylamine incorporated by factor
XIII inlo flbrinogen-coated microtitre plates. The reaction
was started by the addition of thrombin, calcium and
5-(biotinamido) pentylamine. After flxed time intervals
(3 and 10 min), reactions were stopped by the addition of
EDTA and wells were stained for immobilized biotin. This
assay is sensitive both to changes in activation rate and
to changes in speciflc activity of the transglutaminase
formed during activation. It measures the increase of
factor XHIa cross-linking activity within a certain time
interval after thrombin addition and therefore is not an
activity test in the strictest sense. However, very similar
or identical assays have been reported previously äs factor
XIII activity (Kangsadalampai & Board, 1998; Kohler
et al, 1998b; Anwar et al, 1999) and we have followed
this nomenclature.
Factor XIII A and B subunit levels were measured by
sandwich enzyme-linked immunosorbent assay (ELISA)
(Ariens et al, 1999). Both assays used the same polyclonal
antibody against zymogen factor XIII tetramer äs capture
antibody. Each ELISA was then further developed with a
polyclonal antibody speciflc for either the A or the B subunit
(Diagnostica Stago Asnieres, France). The assays were
specific for the A and B subunit; there was no cross-
reactivity with the other subunit äs tested with purified
recombinant factor XIII subunits. The B subunit assay
appeared equally sensitive to both free B subunits äs well äs
to A2B2-subunit complex, äs demonstrated by identical
dose-response curves for pooled normal plasma and B
antigen of a patient homozygous for a severe factor XIII A
deflciency (kindly provided by Dr P. M. Mannucci). All
results are expressed äs the concentration in U/dl, where
l U represents the amount of the analyte in l ml pooled
normal plasma. For one patient, no information on factor
XIII activity or the A and B subunit concentration was
available.
D-dimer levels were measured by ELISA using two
monoclonal antibodies against non-overlapping antigenic
determinants (Declerck et al, 1987). D-dimer levels were
expressed in ng/ml. For 10 patients and seven controls, no
information was available on D-dimer levels.
Factor XIII A2B2-tetramer levels and dissociation index. A
novel sandwich ELISA was developed to measure levels of
the A2B2-subunit complex before and after partial activation
with thrombin (Komanasin et al, 1999). The sugar moiety
of a polyclonal anti-FXIII A IgG (Diagnostica Stago) was
labelled with biotin [Biotin-e-amino-caproyl hydrazide
(BACH); Calbiochem, La Jolla, CA, USA], according to the
method of O'Shannessy (1990). Microtitre plates (Nunc
Maxisorp) were coated with anti-FXIII B IgG (also from
Diagnostica Stago) diluted 1/600 in 50 mmol/1 sodium
carbonate pH 9-6. Non-specific binding sites were blocked
with 150 μΐ 50 mmol/1 Tris-HCl, 150 mmol/1 NaCl, 1%
bovine serum albumin (BSA), OO1% NaN3, pH 7-5. Plasma
samples were diluted 1/400 in 50 mmol/1 Tris-HCl,
150 mmol/1 NaCl, 0-3% NaN3, 0-3% BSA, pH 7-5, and a
total of 100 μΐ was loaded into the wells in duplicate. After
washing four times with 200 μΐ 50 mmol/1 Tris-HCl,
150 mmol/1 NaCl, OO1% NaN3, 0-1% Tween-20, pH 7-5,
100 μΐ of biotinylated anti-FXIII A IgG was added (1/500
dilution). Biotinylated antibody Sandwiches were reacted
with 100 μΐ of 1/500 streptavidin conjugated with alkaline
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phosphatase (Sigma Chemicals, St Louis, USA) and bound
conjugate was detected by addiüon of 100 μΐ of p-nitrophe-
nol phosphate (Sigma Chemicals). Within 15 min of colour
development, the reaction was stopped with 100 μΐ
4 mmol/1 NaOH per well and absorbance was read at 405
and 550 nm. Levels of FXIII A2B2 complex were calculated
from a Standard curve of pooled normal plasma and
expressed in U/dl. Intra-assay coefficient of Variation (CV)
was 5-2% (n = 20) and interassay CV was 6-8% (n = 14).
The factor XIII A2B2-tetramer ELISA can be used to measure
dissociation of the subunits and hence activation. Measure-
ment of the complex before and after activation provided
Information on the percentage of the A2B2-subunit complex
that was dissociated under influence of thrombin and
calcium ions. Dissociation of the factor XIII A2B2 tetramer
was analysed under controlled in vitro conditions that lead
to, on average, 65% activation of factor XIII. Plasma samples
were diluted 1:10 in 50 mmol/1 Tris-HCl, 150 mmol/1 NaCl,
0-3% NaN3, 0-3% BSA, pH 7-5 containing 0-4% Gly-Pro-
Arg-Pro-amide (Sigma Chemicals) to prevent inopportune
polymerization of flbrin. Five microlitres of a mixture of
5 U/ml bovine thrombin (Sigma) and 500 mmol/1 CaCl2
was added to 50 μΐ of diluted plasma. The mixtures were
incubated at room temperature for 30 min and the disso-
ciation reaction was stopped with 10 volumes of 0-1 mol/1
trisodium citrate. Samples were further diluted 1:4 and the
remaining A2B2 complex was measured by ELISA äs
described above.
No data on the dissociation index were available for 10
individuals (three patients and seven controls).
Determination of genotypes. Factor XIII Val34Leu geno-
types were identified using an allele-specific polymerase
chain reaction (PCR) based on a method described by Saiki
et al (1988). Two external primers (primer 1: forward
primer, 5'-ATG TCA GAA ACT TCC AGG AC-3'; primer 2:
reverse primer, 5'-CTG GAC CCA GAG TGG TGG-3') and
two internal forward (nested) primers (primer 3: forward
primer G, 5'-CTG CCC ACA GTG GAG CTT CAG GCC G-3';
primer 4: forward primer T, 5'-CTG CCC ACA GTG GAG CTT
CAG GCC T-3') were designed. The two internal primers
only differ in the last nucleotide, i.e. the G/T base Variation
(FXIII Val34Leu).
The 169 bp DNA fragment produced by the external
primers serves äs a template for either primer 3 or primer 4
and äs an internal control of the PCR reaction. Use of either
primer 3 or 4 äs the third primer in a PCR resulted in the
production of a 91 bp fragment when, respectively, a G or a
T allele was present.
Ampliflcation was carried out using 50 μΐ of sample in
a programmable Thermal Controller (PTC-100™; MJ
Research, Watertown, MA, USA). Each sample contained
100-500 ng genomic DNA, 1-5 mmol/1 of each dNTP,
67 mmol/1 Tris-HCl pH 8-8, 16-6 mmol/1 ammonium sul-
phate, 6-7 mmol/1 MgCl, 10 mmol/1 2-mercaptoethanol,
100 μg/ml bovine serum albumin, 10% dimethylsulphox-
ide, 1-25 units of Amplitaq DNA polymerase and 325 ng of
each primer for genotype determination. The solulion was
overlaid with mineral oil. A flrst denaturation step at 95°C
for 4 min was followed by 34 cycles of l min of denatur-
ation at 95°C, l min annealing at 61°C and 2 min
extension at 67°C. Five microlitres of each amplification
sample was loaded on a 2% agarose gel which was ethidium
bromide stained. The factor XIII Val34Leu polymorphism
was reported äs Val/Val (G/G), Val/Leu (G/T) or Leu/Leu
(T/T). For three patients, no Information on factor XIII
genotype was available.
Statistical analysis. Determinante of factor XIII activity
and A and B subunit levels were evaluated by comparing
means between groups, including only control subjects äs
reflecting the general population.
We investigated whether carrying the factor XIII 34Leu
allele was associated with a decreased venous thrombotic
risk by calculating odds ratlos (OR) and their 95% confid-
ence intervals (95% CI). To calculate the risk of venous
thrombosis associated with increased factor XIII activity or
increased subunit levels, we used the 90th (P90) percentile
measured in the control subjects äs a cut-off point. The P90
of factor XIII activity was 158-9 U/dl, of the A subunit level
P90 was 137Ό U/dl and of the B subunit level P90 was
125-0 U/dl.
We compared factor XIII activity with the results of the
dissociation index in the control subjects, to provide
Information on the activation patterns of the different
Val34Leu genotypes.
As D-dimer, a flbrin degradation product, indicates the
activation of both the fibrinolytic äs well äs the coagulation
System, we included D-dimer levels in the analysis to assess
the overall effecl of the factor XIII genotype on flbrin
formation and dissociation.
RESULTS
The mean age of the patients and the controls at the time of
the thrombosis was 45 years (ränge patients 15-69,
controls 15-72). Among both patients and controls, 57%
were women. The frequency of the Leu allele was 0-22 in
the patients and 0-24 in the control subjects. The distribu-
tion of the factor XIII Val34Leu in the control subjects was
according to the Hardy-Weinberg equilibrium.
Factor XIII activity and subunit levels
In Table I, the results of the factor XIII activity and A and B
subunit levels, measured in the healthy control subjects, are
shown by genotype, age, sex and oral contraceptive use.
Factor XIII activity was positively associated with the Leu
allele and increasing age, but not with oral contraceptive
use and sex [linear regression coefflcients with factor XIII
activity äs dependent variable: FXIII genotype (0 = Val/Val,
l = Val/Leu, 2 = Leu/Leu) ß: 33-9 (95%CI: 29-9-37-8),
Age (per 10 years increase) ß: 2-8 (95%CI: 0-6-5-0), oral
contraceptive use (0 = no, l = yes) ß: 10-5 (95%CI: -0-9-
21-9), sex (0 = female, l = male) ß: 1-1 (95%CI: -5-0-
7-2)]. The effect of the genotype was pronounced, with more
than 60% higher levels for the Leu/Leu genotype (mean:
158-0 U/dl) compared with the Val/Val genotype (mean:
95-0 U/dl). The A and B subunit levels were positively
associated with increasing age, but not with sex, genotype
or oral contraceptive use [linear regression coefflcients with
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Table I Mean (SD) of factor XIII activity and factor XIII A and B subumt levels (U/dl) measured
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*At the time of the venepuncture (women aged 15-49 years who were not prägnant not withm
30 d postpartum did not have a recent miscarnage and did not use depot contraceptives)
factor XIII A subumts äs dependent variable age (per
10 years increase) β 39 (95%CI 24-54), sex β 19
(95%CI -23-62), FXIII Val34Leu -32 (95%CI -66-
03), oral contraceptives β -22 (95%CI -102-57),
linear regression coefflcients with factor XIII B subumts äs
dependent variable age (per 10 years increase) β 3 7
(95%CI 25-48), sex β 32 (95%CI -02-65), FXIII
Val34Leu 00 (95%CI -27-28), oral contraceptives β
34 (95%CI -2 1-89)]
Risk of deep venous thrombosis
Table II shows the nsk of venous thrombosis for mdividuals
who carned the factor XIII 34Leu allele compared with
mdividuals homozygous for the 34Val allele The nsk of
deep venous thrombosis was reduced by 10% for heterozy-
gous carners of the factor XIII 34Leu allele [OR 0 9 (95%
CI 0 7-1 2)] and by 30% for mdividuals homozygous for
the 34Leu allele [OR 07 (95% CI 04-13)] This effect
stood out more clearly with increasing age and was
completely restncted to men
Usmg the 90th percentile measured m the control
subjects äs a cut-off pomt for factor XIII activity and A
and B subumt levels, we calculated the nsk of deep venous
thrombosis associated with increased factor XIII activity and
increased subumt levels Individuais with high factor XIII
activity had a slightly lower nsk of thrombosis compared
with mdividuals with factor XIII activity below the cut-off
value [factor XIII activity >P90 OR 0 8 (95% CI 0 5-1 3),
factor XIII activity >P95 OR 03 (95% CI 01-07)]
Increased A and B subumt levels (> P90) were associated
with a weak increase in thrombotic risk [ORA subumt l 4
(95%CI 0 9-2 2), ORB subumt l 6 (95%CI 11-24)]
Table III shows the associations of the factor XIII
genotypes and factor XIII activity with the A2B2-dissoci-
ation index Individuais with the factor XIII 34Leu allele
had a higher dissociation mdex i e in these mdividuals















































































*A11 ORs calculated with factor XIII Val/Val (wild type) äs a reference category
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Table III Mean (SD) of levels of the factor XIII A2B2-subumt complex before and after thrombin activation and the factor XIII dissociation
mdex measured m 467 healthy control subjects (no plasma samples available for seven control subjects)
A2B2-subumt complex A2B2-subumt complex Factor XIII dissociation mdex
before thrombin after thrombm [(before-after)/before]
































































more A2B2-subumt complex was dissociated under con-
trolled in vitro activation conditions (see Materials and
methods) Higher factor XIII activity was associated with an
increased dissociation mdex (linear regression coefficient
with factor XIII activity äs dependent variable β 11,95%
CI 09-13)
Individuais homozygous Leu/Leu had slightly lower
D-dimer levels compared with individuals with the wild-
type genotype Mediän D-dimer levels measured m the
control group were GG 75 3 (ränge 4 0-1608 9), GT 75 8
(ränge 16 5-1229 5), TT 69 5 (ränge 22 3-1940)
DISCUSSION
We studied the relationship between factor XIII Val34Leu
and factor XIII activity and subumt levels m a large case-
control study Our aim was to classify the association
between factor XIII VaB4Leu and factor XIII laboratory
phenotypes, and their effect on thrombotic nsk This would
provide more msight mto the effect of this polymorphism on
the nsk of venous thrombosis
Whereas there was a strong association between factor
XIII Val34Leu and factor XIII activity, we found no effect of
factor XIII Val34Leu genotypes on A and B subumt levels
These results conflrmed that Val34Leu does not have an
effect on circulating factor XIII subumt levels and were m
agreement with earlier studies (Ariens et al, 2000, Balogh
et al, 2000, Wartiovaara et al, 2000) that reported an
increased factor XIII activation rate associated with the
factor XIII 34Leu allele Apparently, under our assay
conditions, the increased activation of factor XIII 34Leu
contnbuted to the factor XIII activity Upon füll activation
by thrombin, however, both forms of factor XIII show equal
speciflc cross-lmking activity (Ariens et al, 2000, Wartiova-
ara et al, 2000) The pentylamme incorporation assay, äs it
is routmely used to measure factor XIII activity levels,
appeared to be very sensitive to changes m the kmetics of
the activation of factor XIII by thrombin and, therefore, to
the Val34Leu polymorphism It was shown that increased
factor XIII activity was associated with a slightly decreased
risk of thrombosis [OR 0 8 (95% CI 0 5-1 3)] that was of
the same magmtude äs the decreased nsk associated with
factor XIII 34Leu allele carners The thrombotic nsk
associated with elevated levels of both the A and the B
subumt levels was not decreased but even slightly increased
Individuais with the factor XIII 34Leu allele had a higher
factor XIII dissociation mdex under conditions of controlled
m vitro activation of factor XIII These results mdicate that,
under these conditions, m individuals homozygous for factor
XIII 34Leu more A2B2-tetramer was dissociated under these
conditions, than m individuals homozygous for factor XIII
34Val When we analysed the A2B2-subunit complex before
and after thrombm activation and the dissociation mdex m
relation to the three categones of factor XIII activity
(Table III), we found that higher activity was associated
with a higher dissociation mdex These results conflrmed
that the increased activity in individuals homozygous for the
Leu allele appeared to be caused by an increased activation
rate of the factor XIII 34Leu vanant by thrombin
We found a slightly decreased nsk of venous thrombosis
for individuals with the factor XIII 34Leu allele compared
with individuals homozygous for the wild-type 34Val allele,
but the effects were small, with no more than a 10% nsk
reduction for heterozygous factor XIII 34Leu carners [OR
0 9 (95% CI 0 7-1 2)] The effect was more apparent m
individuals homozygous for the 34Leu allele [OR 0 7 (95%
CI 0 4-1 3)]
A number of studies with varymg results on the effect of
the factor XIII Leu allele have been reported Several studies
reported a protective effect of the 34Leu allele on the risk of
deep venous thrombosis (Catto et al, 1999, Alhenc-Gelas
et al, 2000, Renner et al, 2000), while others reported no
effect (Balogh et al, 2000, Corral et al, 2000, Margaghone
et al, 2000) In a study by Franco et al (1999) only
individuals homozygous for the factor XIII 34Leu allele had
a decreased thrombotic risk
The weak nature of the protective effect of FXIII
Val34Leu means that even m a large study such äs ours,
we cannot confldently exclude the absence of an effect
and, similarly, the studies that did not see protection
(Balogh et al, 2000, Corral et al, 2000, Margaghone et al,
2000) could not exclude a small effect Unexpectedly, the
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Fig 1. Comparison of odds ratios and 95% confidence intervals for
the total group of carriers of the Leu allele (GT + TT) compared with
the wild-type genotype (GG). Studies: (A) Corral et al (2000), patients
n = 97, controls n = 97; (B) Franco et al (1999), patients n = 189,
controls n = 187; (C) Balogh et al (2000), patients n = 273,
controls n = 288; (D) Renner et al (2000), patients n = 154, con-
trols n = 308; (E) Margaglione et al (2000), patients n = 427,
controls n = 1045; (F) Catto et al (1999), patients n = 217, con-
trols n = 252; (G) PATHROS, Alhenc-Gelas et al (2000), patients
n = 354, controls n = 1229; (H) LETS, patients n = 471, controls
n = 474; (I) Overall risk estimate of all eight studies, OR Mantel-
Haenszel.
protective effect we found was restricted to men. This
difference in effect of factor XIII VaI34Leu between sexes
remains unexplained.
As a number of studies with varying results on the effect
of factor XIII Val34Leu on the risk of deep venous
thrombosis have been published, we proceeded to calculate
an Overall risk estimate using the Mantel-Haenszel proce-
dure (Fig 1). We performed a PubMed search on the
keywords 'Val34Leu' or 'Val 34 Leu' and 'thrombosis'. In
total, we found 15 articles of which nine contained data
from studies on venous thrombosis. We selected only those
articles in which a risk associated with the factor XIII 34Leu
allele compared with the factor XIII wild-type genotype was
reported or when we could calculate the risk from the data
in the paper. One study only included individuals carrying
the factor V Leiden mutation (Franco et al, 2000b) and was
therefore excluded. The studies that were included for this
calculation were: Catto et al (1999), Franco et al (1999),
Alhenc-Gelas et al (2000), Balogh et al (2000), Corral et al
(2000), Margaglione et al (2000), Renner et al (2000), and
the results of the current study (LETS). The pooled risk
estimates were similar to the results found in the current
study: ORMH (Val/Leu): 0-9 (95% CI: 0-8-1-0); ORMH (Leu/
Leu): 0-8 (95% CI: 0-6-1-0); ORMH (Val/Leu + leu/Leu): 0-9
(95% CI: 0-8-1-0).
The design of the studies used in this calculation differed
in some points. Some studies included both patients with
deep venous thrombosis äs well äs patients with pulmonary
embolism, while others only included patients with deep
venous thrombosis. Another difference was that in some
studies various patient groups with venous thrombosis were
included (Catto et al, 1999; Franco et al, 1999; Alhenc-
Gelas et al, 2000; Corral et al, 2000; Renner et al, 2000),
while in other studies patients were selected on thrombo-
philia screening or family history (Balogh ei al, 2000;
Margaglione et al, 2000). Preferably, a meta-analysis
includes studies with a similar design. When only the
studies with various patient groups were included in the
meta-analyses, the pooled effect became more pronounced:
ORMH (Val/Leu): 0-8 (95% CI: 0-7-1-0); ORMH (Leu/Leu):
0-6 (95 CI: 0-4-0-8); ORMH (Val/Leu + leu/Leu): 0-8
(95 CI: 0-7-0-9). It may be that a mild protective effect
caused by the factor XIII 34Leu allele was no longer
observed when other thrombotic risk factors were present
in these selected patients with suspected familial
thrombophilia.
In the present study, we found a weak protective effect on
the risk of venous thrombosis of the factor XIIIVal34Leu
polymorphism. This effect was somewhat more pronounced
in the results of the meta-analysis. This effect appeared to
be reslricted to men. Additionally the 34Leu phenotype was
associated with increased factor XIII cross-linking activity
and enhanced dissociation of the factor ΧΠΙΑ2Β2 complex.
These results support the hypothesis that a protective effect
of factor XIII 34Leu is mediated through a laboratory
phenotype of an increased activation rate. The risk esli-
mates we calculated were all minor compared with other
risk factors for thrombosis and evaluation of this genotype
will have no relevance for clinical care.
The factor XIII 34Leu genotype was associated with
slightly lower D-dimer levels. D-dimer is a speciflc degrada-
tion product of cross-linked fibrin. Lower D-dimer levels
could be the result of reduced fibrinolysis caused by a clot
which is more lysis resistant. As the factor XIII 34Leu
genotype appeared to be associated with a weak protective
effect on the risk of venous thrombosis, this does not seem
likely. The lower D-dimer levels associated with the factor
XIII 34Leu allele could also be the result of reduced fibrin
formation. The results of this study would support this view,
although further in vitro studies are required to evaluate this
point.
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